Market Intelligence, Preclinical and Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GLUT4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLUT4 Full-length Membrane Protein (Custom, HEK293 expressed, native glycosylation, >90% purity, <1 EU/µg endotoxin) and Extracellular Loop (ECL) Recombinant Protein (sequence verified, >95% purity). Both options preserve native 12-TM topology. | View GLUT4 Products |
| Gene Delivery | GLUT4 Lentivirus Premade Particles (full-length SLC2A4 ORF in pLenti-CMV-Puro, titer >10^7 TU/mL, endotoxin controlled) for stable cell line generation with native membrane folding. | View GLUT4 Products |
| Benchmark Ab | Anti-GLUT4 Monoclonal Antibody (recombinant, sequence verified, validated for Flow Cytometry, IF, and Western Blot; recognizes extracellular epitope for surface staining). | View GLUT4 Products |
| Validator | GLUT4 siRNA Set (three unique target-specific sequences, sequence verified) for knockdown verification and basal vs. stimulated uptake specificity. | View GLUT4 Products |
| Related Target: GLUT1 | SLC2A1 (GLUT1) – Basal glucose transporter. Essential for selectivity counter-screening vs. insulin-dependent transport to avoid off-target neurotoxicity. | View SLC2A1 Products |
| Related Target: TBC1D4 | AS160 (TBC1D4) – Rab-GAP regulator of GLUT4 vesicle translocation. Upstream signaling node for pathway synergy and resistance mechanism studies. | View TBC1D4 Products |
| Related Target: INSR | Insulin Receptor (INSR) – Upstream activator of GLUT4 translocation. Critical for insulin signaling pathway analysis. | View INSR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex multi-pass structure (12 TMDs) and intracellular localization | Lentivirus-mediated stable expression in HEK293/adipocyte models preserves native folding and membrane integration. Sequence verified. Endotoxin controlled. |
| Translocation detection (plasma membrane vs. vesicular) | Anti-GLUT4 antibodies (extracellular epitope) strictly verified for surface staining by Flow Cytometry; high signal-to-noise ratio. |
| Family selectivity (vs. GLUT1–GLUT3 and other SLC2A isoforms) | Human/Mouse/Rat ortholog SLC2A panels available; strict sequence homology verified by theoretical MW alignment and flow cytometry. |
| Lack of validated controls and false positives in uptake assays | Validated siRNA set included for target-specific knockdown confirmation. Parallel cell lines expressing related isoforms enable counter-screening. |
Live GLUT4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GLUT4-targeted therapeutics is bifurcating between metabolic activation and oncologic inhibition. As a principal insulin-responsive glucose transporter in muscle and adipose tissue, GLUT4 represents a high-value target for Type 2 Diabetes and insulin resistance. However, its intracellular sequestration and 12-transmembrane topology present formidable druggability challenges. The field is shifting from traditional biochemical binding assays toward cell-based phenotypic screening that measures glucose uptake and translocation dynamics. Concurrently, emerging evidence of GLUT4 overexpression in breast and prostate cancers has spurred interest in selective inhibitors that may disrupt the Warburg effect in specific tumor subtypes without systemic metabolic toxicity. The pipeline remains predominantly preclinical, with first-generation metabolic therapies reaching clinical maturity and next-wave R&D targeting localized GLUT4 activation via small molecule allosteric modulators and translocation enhancers. As GLP-1 receptor agonist therapies expand, subsequent waves are investigating GLUT4-targeted combinatorial approaches to manage residual hyperglycemia and tissue-specific glucose transport deficits.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Translocation Enhancers | Metabolic biotechs, academic consortia | Type 2 Diabetes, Insulin Resistance | Functional glucose uptake assay (requires stable GLUT4 cell lines via lentivirus) |
| Small Molecule Allosteric Inhibitors | Oncology startups | Breast Cancer, Prostate Cancer | Competition binding assay (requires intact membrane protein in native conformation) |
| Chemical Chaperones | Rare disease foundations | Lipodystrophy | Trafficking assay (needs lentivirus-expressed reporter constructs) |
| Peptide Therapeutics | Novo Nordisk, research institutes | Metabolic Syndrome, Obesity | Translocation assay (need benchmark antibodies for flow cytometry) |
| Gene/Cell Therapy (Overexpression) | Rare disease gene therapy platforms | Monogenic insulin resistance, Lipodystrophy | Stable ORF delivery (high-titer GLUT4 lentivirus for cell engineering) |